IWS1: A Protein with Potential as A Drug Target and Biomarker

Target Name: IWS1

NCBI ID: G55677

IWS1

IWS1: A Protein with Potential as A Drug Target and Biomarker

IWS1 (IWS1-like protein) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the IWS family of proteins, which are known for their role in regulating inflammation and autophagy. While the exact function of IWS1 is not yet fully understood, research has shown that it plays a key role in the regulation of cellular processes that are important for maintaining tissue health and function.

One of the key functions of IWS1 is its ability to interact with other proteins that are involved in the regulation of inflammation and autophagy. These proteins include AIM1 (AIM1-like protein), which is known for its role in regulating the production of pro-inflammatory cytokines, and MAM (Mammalian AIM-1-like protein), which is also involved in the regulation of inflammation and autophagy.

IWS1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. For example, studies have shown that IWS1 is involved in the regulation of cell adhesion and cell-cell interactions, as well as the regulation of cell migration and the maintenance of tissue structure.

In addition to its role in the regulation of cellular processes, IWS1 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that IWS1 is often overexpressed in various types of cancer, and that overexpression of IWS1 has been associated with the development of cancer.

Given the significance of IWS1's role in the regulation of cellular processes and its involvement in the development and progression of various diseases, it is a promising target for drug development. Researchers are currently working to develop compounds that can specifically target IWS1 and modulate its activity, with the goal of using these compounds as therapeutic agents for a variety of diseases.

In addition to its potential as a drug target, IWS1 is also a potential biomarker for the diagnosis and prognosis of various diseases. For example, studies have shown that IWS1 is often expressed in various types of cancer, and that its levels are often elevated in individuals with cancer. Therefore, IWS1 may be a useful biomarker for the diagnosis and prognosis of cancer.

Overall, IWS1 is a protein that has significant potential as a drug target and biomarker. Further research is needed to fully understand its role in the regulation of cellular processes and its involvement in the development and progression of various diseases.

Protein Name: Interacts With SUPT6H, CTD Assembly Factor 1

Functions: Transcription factor which plays a key role in defining the composition of the RNA polymerase II (RNAPII) elongation complex and in modulating the production of mature mRNA transcripts. Acts as an assembly factor to recruit various factors to the RNAPII elongation complex and is recruited to the complex via binding to the transcription elongation factor SUPT6H bound to the C-terminal domain (CTD) of the RNAPII subunit RPB1 (POLR2A). The SUPT6H:IWS1:CTD complex recruits mRNA export factors (ALYREF/THOC4, EXOSC10) as well as histone modifying enzymes (such as SETD2) to ensure proper mRNA splicing, efficient mRNA export and elongation-coupled H3K36 methylation, a signature chromatin mark of active transcription

The "IWS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IWS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets